Revue des Maladies Respiratoires Actualites最新文献_第4页

La chirurgie du cancer du poumon localisé en 2024 2024年定位肺癌手术

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/S1877-1203(25)00064-3

G. Drevet , E. Gagnepain , J.-M. Maury

引用次数: 0

Quand et comment réaliser un staging ganglionnaire ? 什么时候以及如何进行节育器阶段？

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/S1877-1203(25)00063-1

D. Basille

{"title":"Quand et comment réaliser un staging ganglionnaire ?","authors":"D. Basille","doi":"10.1016/S1877-1203(25)00063-1","DOIUrl":"10.1016/S1877-1203(25)00063-1","url":null,"abstract":"<div><div>Mediastinal lymph node staging is a critical step in the therapeutic management of non-small cell lung cancer (NSCLC). Advances in functional imaging, particularly PET-CT, have significantly improved non-invasive diagnosis. However, its limited specificity makes histological confirmation essential.</div><div>Minimally invasive endoscopic techniques, endobronchial ultrasound (EBUS) ± endoscopic ultrasound (EUS), have emerged as first-line modalities due to their low morbidity and high diagnostic accuracy, especially in patients eligible for curative treatment. These techniques are particularly recommended in cases of radiologically suspicious lymphadenopathy (cN1-N3), central tumors, or large tumors (>3 cm). In the event of negative findings but persistent clinical suspicion, surgical staging via mediastinoscopy remains indicated. Nevertheless, the systematic use of this surgical approach following complete endoscopic staging is increasingly debated in light of recent evidence.</div><div>In patients with early-stage NSCLC classified as N0 on PET, invasive staging prior to stereotactic body radiotherapy is not routinely recommended but should be considered on a case-by-case basis, depending on clinical and anatomical risk factors.</div><div>Finally, in locally advanced disease treated with neoadjuvant therapy, mediastinal restaging remains a pivotal step in guiding further management. However, it is technically more challenging due to treatment-induced changes such as fibrosis and adhesions, and requires an individualized approach combining both endoscopic and surgical techniques. 1877-1203/© 2025 SPLF. Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S75-2S83"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Admission en unité de soins critiques et niveau de réanimation : application au cancer du poumon ? 重症监护住院和复苏水平：肺癌的应用？

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/S1877-1203(25)00088-6

G. Dumas , C. Ardin , G. Berardi , F. Gonzalez , A.-C. Toffart

{"title":"Admission en unité de soins critiques et niveau de réanimation : application au cancer du poumon ?","authors":"G. Dumas , C. Ardin , G. Berardi , F. Gonzalez , A.-C. Toffart","doi":"10.1016/S1877-1203(25)00088-6","DOIUrl":"10.1016/S1877-1203(25)00088-6","url":null,"abstract":"<div><div>Patients with lung cancer are at high risk of developing organ failures, either directly related to the disease itself or as a consequence of its treatment, which may require admission to the intensive care unit (ICU). Such an event represents a major turning point in the patient's care pathway and remains associated with high morbidity and mortality. Recently, advances in targeted therapies and immunotherapy have significantly altered the clinical trajectory of patients with non-small cell lung cancer, prompting a reevaluation of ICU admission strategies, particularly in the context of acute respiratory failure. ICU admission decisions—as well as the intensity of organ support—must always be individualized and based on a tripartite discussion between the patient, the intensivist, and the oncologist. The aim is to establish a realistic and personalized care plan. Key elements in this decision-making process include the assessment of patient frailty, the tumor history, the number and expected reversibility of organ failures (and their underlying causes), as well as the patient's goals and family expectations.</div><div>In this review, we summarize the factors associated with ICU survival in patients with bronchial cancer—whether patient-related, tumor-related, or linked to the acute event. We then focus on the specific case of acute respiratory failure, examining its reversibility, prognosis, and the etiologic and supportive therapies that should be considered. 1877-1203/© 2025 SPLF. Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S305-2S310"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anticorps thérapeutiques innovants dans le cancer bronchique non à petites cellules : au-delà des cibles classiques 非小细胞肺癌的创新治疗性抗体：超越常规靶点

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/S1877-1203(25)00075-8

E. Pons-Tostivint , J. Bennouna

{"title":"Anticorps thérapeutiques innovants dans le cancer bronchique non à petites cellules : au-delà des cibles classiques","authors":"E. Pons-Tostivint , J. Bennouna","doi":"10.1016/S1877-1203(25)00075-8","DOIUrl":"10.1016/S1877-1203(25)00075-8","url":null,"abstract":"<div><div>Therapeutic antibodies have profoundly reshaped the management of non-small cell lung cancer (NSCLC). Following initial strategies targeting VEGF or EGFR, the introduction of immune checkpoint inhibitors (anti-PD-1 /PD-L1) represented a major breakthrough. However, primary and acquired resistance still limit their efficacy, prompting the development of innovative antibodies.</div><div>Antibodies directed against novel immune checkpoints (LAG-3, TIGIT, TIM-3, NKG2A) aim to restore the functionality of exhausted T lymphocytes. Early clinical results are mixed, with some signals of efficacy but also several failures in late-phase trials.</div><div>Bispecific antibodies such as amivantamab (anti-EGFR/MET), ivonescimab (anti-PD-1/VEGF), and tarlatamab (anti-DLL3/CD3) are emerging as promising options. By combining tumor targeting with immune modulation, they have demonstrated significant clinical benefits in phase 3 studies, notably in terms of overall survival and tolerability. Other experimental constructs, including bi- or tri-specific formats, T-cell engagers, and nanobodies, are under investigation and may further expand therapeutic indications.</div><div>Key challenges remain the identification of reliable predictive biomarkers, the management of specific toxicities (particularly cytokine release syndrome), and the validation of their role in therapeutic algorithms. Advances in multiomic profiling and artificial intelligence could improve patient selection and anticipate resistance mechanisms. Overall, next-generation therapeutic antibodies represent a promising strategy for NSCLC patients, provided that current biological and clinical hurdles can be overcome. 1877-1203/© 2025 SPLF. Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S180-2S191"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable au-delà de la première ligne 无分子异常的CBNPC治疗算法，可在一线以外操作

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/S1877-1203(25)00073-4

M. Pérol , D. Moro-Sibilot

{"title":"Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable au-delà de la première ligne","authors":"M. Pérol , D. Moro-Sibilot","doi":"10.1016/S1877-1203(25)00073-4","DOIUrl":"10.1016/S1877-1203(25)00073-4","url":null,"abstract":"<div><div>Despite the improved results of first-line treatment of metastatic non-small-cell lung carcinoma with anti PD-(L)1, the majority of patients continue to experience disease progression, reflecting primary or acquired resistance to immunotherapy. “Second-line” treatment follows anti PD-(L)1 immunotherapy and platinum-based doublet chemotherapy, administered either sequentially or concomitantly. The multiplicity of mechanisms of resistance to immunotherapy makes it difficult to identify them at the level of a given patient; the majority of therapeutic strategies developed in the second-line setting are therefore agnostic of the mechanism of resistance to immunotherapy. Despite the development of numerous innovative strategies, treatment remains based on cytotoxic chemotherapy, mainly taxanes as monotherapy or combined with anti-angiogenic agents. It remains important to check the absence of genomic or phenotypic alterations that could be accessible to a specific treatment, particularly in the context of a clinical trial. For the time being, the development of conjugated antibodies has not transformed the second-line strategy, and is now mainly conducted in the first-line setting. Rechallenge with immunotherapy can only be envisaged after anti PD-(L)1 has been discontinued due to toxicity, or after the scheduled end of first-line treatment, after a free interval. New strategies are currently being studied to overcome primary or acquired resistance to immunotherapy.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S160-2S170"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145236540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

La radiothérapie des cancers du poumon non à petites cellules localement avancés 局部晚期非小细胞肺癌的放射治疗

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/S1877-1203(25)00067-9

I. Martel-Lafay

引用次数: 0

Éditorial : Cours du Groupe d'Oncologie Thoracique de Langue Française 2025 编者：2025年法语胸腔癌小组课程

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI: 10.1016/S1877-1203(25)00053-9

M. Duruisseaux, S. Couraud, A.-C. Toffart, A. Swalduz

引用次数: 0

Physiologie respiratoire 呼吸生理学

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-07-30 DOI: 10.1016/j.rmra.2025.07.001

引用次数: 0

Infectiologie respiratoire 抗呼吸道

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-07-31 DOI: 10.1016/j.rmra.2025.07.002

引用次数: 0

Soins intensifs respiratoires 呼吸强化护理

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-08-05 DOI: 10.1016/j.rmra.2025.07.003

引用次数: 0